<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title>renalbone.knit</title>

<script src="site_libs/header-attrs-2.28/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/jqueryui-1.13.2/jquery-ui.min.js"></script>
<link href="site_libs/tocify-1.9.1/jquery.tocify.css" rel="stylesheet" />
<script src="site_libs/tocify-1.9.1/jquery.tocify.js"></script>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/font-awesome-6.4.2/css/all.min.css" rel="stylesheet" />
<link href="site_libs/font-awesome-6.4.2/css/v4-shims.min.css" rel="stylesheet" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>







<link rel="stylesheet" href="styles.css" type="text/css" />



<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->



<style type="text/css">

#TOC {
  margin: 25px 0px 20px 0px;
}
@media (max-width: 768px) {
#TOC {
  position: relative;
  width: 100%;
}
}

@media print {
.toc-content {
  /* see https://github.com/w3c/csswg-drafts/issues/4434 */
  float: right;
}
}

.toc-content {
  padding-left: 30px;
  padding-right: 40px;
}

div.main-container {
  max-width: 1200px;
}

div.tocify {
  width: 20%;
  max-width: 260px;
  max-height: 85%;
}

@media (min-width: 768px) and (max-width: 991px) {
  div.tocify {
    width: 25%;
  }
}

@media (max-width: 767px) {
  div.tocify {
    width: 100%;
    max-width: none;
  }
}

.tocify ul, .tocify li {
  line-height: 20px;
}

.tocify-subheader .tocify-item {
  font-size: 0.90em;
}

.tocify .list-group-item {
  border-radius: 0px;
}

.tocify-subheader {
  display: inline;
}
.tocify-subheader .tocify-item {
  font-size: 0.95em;
}

</style>



</head>

<body>


<div class="container-fluid main-container">


<!-- setup 3col/9col grid for toc_float and main content  -->
<div class="row">
<div class="col-xs-12 col-sm-4 col-md-3">
<div id="TOC" class="tocify">
</div>
</div>

<div class="toc-content col-xs-12 col-sm-8 col-md-9">




<div class="navbar navbar-default  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">Renal Medicine</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    Research
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./trials.html">Metro North KHS Trials</a>
    </li>
    <li>
      <a href="./Research_MN_output.html">Metro North KHS Research output</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    GEN
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./HTN.html">HTN</a>
    </li>
    <li>
      <a href="./CCF.html">CCF</a>
    </li>
    <li>
      <a href="./DKD.html">DKD</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    U&amp;E
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./acidbase.html">H+ &amp; HCO3</a>
    </li>
    <li>
      <a href="./na.html">Na</a>
    </li>
    <li>
      <a href="./k.html">K</a>
    </li>
    <li>
      <a href="./mg.html">MG</a>
    </li>
    <li>
      <a href="./renalbone.html">Ca2+ &amp; PO4</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    GN
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./MCD.html">MCD</a>
    </li>
    <li>
      <a href="./ANCA.html">ANCA</a>
    </li>
    <li>
      <a href="./IGAN.html">IGAN</a>
    </li>
    <li>
      <a href="./MPGN_C3G.html">MPGN &amp; C3G</a>
    </li>
    <li>
      <a href="./LUPUS.html">LUPUS</a>
    </li>
    <li>
      <a href="./FSGS.html">FSGS</a>
    </li>
    <li>
      <a href="./TMA.html">TMA</a>
    </li>
    <li>
      <a href="./GBM.html">GBM</a>
    </li>
    <li>
      <a href="./MN.html">MN</a>
    </li>
    <li>
      <a href="./Amyloid.html">Amyloid</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    CKD
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./project1.html">Checklist</a>
    </li>
    <li>
      <a href="./project1.html">Conservative care</a>
    </li>
    <li>
      <a href="./anaemia.html">Anaemia</a>
    </li>
    <li>
      <a href="./project1.html">Pruritis</a>
    </li>
    <li>
      <a href="./renalbone.html">CKD-MBD</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    TX
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./project1.html">Cheat sheet</a>
    </li>
    <li>
      <a href="./txnotes.html">Misc Notes</a>
    </li>
    <li>
      <a href="./nonkidneytx.html">Non Kidney Tx</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    RRT
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./HD.html">HD</a>
    </li>
    <li>
      <a href="./project1.html">Home HD</a>
    </li>
    <li>
      <a href="./project1.html">HD Access</a>
    </li>
    <li>
      <a href="./project1.html">PD</a>
    </li>
    <li>
      <a href="./project1.html">CVVH</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    DRUGS
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./anticoagulation.html">Anticoagulation</a>
    </li>
    <li>
      <a href="./PJP.html">PJP</a>
    </li>
    <li>
      <a href="./abx.html">Abx</a>
    </li>
    <li>
      <a href="./aboutme.html">HDU</a>
    </li>
    <li>
      <a href="./project1.html">Flozins</a>
    </li>
    <li>
      <a href="./rituxcyc.html">RITUX &amp; CYC</a>
    </li>
    <li>
      <a href="./Chemotherapy.html">Chemo</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    MISC
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./biopsy.html">Biopsy</a>
    </li>
    <li>
      <a href="./path.html">PATH</a>
    </li>
    <li>
      <a href="./preg.html">Pregnancy</a>
    </li>
    <li>
      <a href="./project1.html">PEX</a>
    </li>
    <li>
      <a href="./Lymphoproliferative.html">Lymphoproliferative</a>
    </li>
    <li>
      <a href="./covid19.html">SARS-Cov-2</a>
    </li>
    <li>
      <a href="./Tumour_Lysis.html">Tumour Lysis Syndrome</a>
    </li>
    <li>
      <a href="./Single Kidney.html">Single Kidney</a>
    </li>
    <li>
      <a href="./IGG4.html">IGG4</a>
    </li>
    <li>
      <a href="./Stones.html">Stones</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    Resources
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./edu.html">Educational Resources</a>
    </li>
    <li>
      <a href="./patient_resources.html">Patient Resources</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https:eoindosullivan.com">
    <span class="fas fa-home"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">




</div>


<div id="ckd-mbd-calcium-phosphate." class="section level1">
<h1>CKD-MBD &amp; Calcium &amp; Phosphate.</h1>
</div>
<div id="calcium" class="section level1">
<h1>Calcium</h1>
<div id="physiology---calcium" class="section level2">
<h2>Physiology - Calcium</h2>
<ul>
<li>Freely filtered then about 98% is reabsorbed by the kidney tubules
<ul>
<li><strong>Paracellular</strong>: PT 65%, TAL 25%</li>
<li>In TAL, tight junctions express claudin 16/19, which facilitates
paracellular calcium reabsorption, and claudin 14, which suppresses
it.</li>
<li><strong>PTH</strong> inhibits the expression of claudin 14 ( i.e. it
inhibits the brakes - thus increases calcium reaborbtion)</li>
<li><strong>Transcellular</strong>: DCT/CNT 8%</li>
<li>Active transport</li>
<li><strong>PTH</strong> binds basolaterally, stimulates protein kinase
A,C -&gt; increased TRVP5 channels on apical surface -&gt; more calcium
leaves the urine and reenteres blood</li>
</ul></li>
<li>Mostly reabsorbed in proximal tubule alongside sodium and water
<ul>
<li><p>This is part of the “bonus sodium” you get from NKCC due to K+
recycling. The K+ that gets pumped back into the tubule via ROMK (see
below) leads to a relative +charge in the tubule, thus providing a
charge to help drive the paracellular reabsorbtion ofNa/Ca/Mg via the
rather leaky paracellular junctions in the PT.</p></li>
<li><p>In a high salt diet, there is too much tubular Na so less PT
reabsorbtion of the calcium as there is less drive to reabsorb the
Na</p></li>
<li><p>Which is why you tell calcium stone patients to cut out
Salt</p></li>
<li><p>Thus urinary calcium rises -&gt; calcium stones!</p></li>
</ul></li>
<li>~1-2% (~100-200mg of calcium) is excreted in the urine per day.</li>
</ul>
</div>
<div id="physiological-pearls" class="section level2">
<h2>Physiological pearls</h2>
<ul>
<li>Hypercalcaemia induces volume contraction in two ways:
<ul>
<li>nephrogenic DI: Decreased aquaporin expression in Collecting duct,
possibly via <a
href="https://pubmed.ncbi.nlm.nih.gov/28139295/">increased
autophagy</a></li>
<li>increased basolateral calcium switches off the ROMK channel in PT,
thus shutting down K+ recycling. K+ is the rate limiting step here in
NKCC activity (because N and 2Cl get pumped out basolaterally there is
alot less K to begin with in the tubule). This means that NKCC grinds to
a halt without the recycled K, and the tubule Na/Cl/H20 increases and is
removed, just like a loop diuretic leading to volume depletion.</li>
</ul></li>
</ul>
</div>
<div id="pth" class="section level2">
<h2>PTH</h2>
<ul>
<li><p>If investigating high PTH, sestamibi to check glands for
activity.</p></li>
<li><p>primary hyperPTH commonest cause , 50 per 100,000 patient
years</p></li>
<li><p>Urine calcium is high due to hyperPTH the filtered load will be
too high to reabsorb so will overpower PTH’s reaborbative action and
result in hypercaliuria</p></li>
</ul>
</div>
<div id="hypercalcaemia" class="section level2">
<h2>HyperCalcaemia</h2>
<ol style="list-style-type: decimal">
<li>Check iPTH</li>
</ol>
<p><strong>HIGH or inappropriately normal PTH</strong></p>
<ul>
<li>24 hour urinary calcium or urine calcium creatinine ratio high =
<strong>Primary hyperPTH</strong></li>
<li>If less than these values, possibly <strong>familial hypocaliuric
hypercalcaemia</strong>
<ul>
<li>family history, asymptomatic</li>
<li>benign condition / inactivating mutation in the calcium-sensing
receptor /increased tubular reabsorption of calcium and consequent low
urinary calcium excretion.</li>
<li>PTH can be normal or <em>slightly</em> elevated</li>
<li>Diagnosis of hypocalciuric Hypercalcaemia - 24 h urine
calcium/creatinine clearance ratio &lt; 0.01.</li>
</ul></li>
</ul>
<p><strong>LOW PTH</strong></p>
<p>Myeloma screen, cancer hunt, Vit D, PTHrp</p>
<ul>
<li>High PTHrp - humoural hypercalcaemia of malignancy</li>
<li>High 25(OH)D - Too much vit D</li>
<li>High 1,25(OH)D - lymphoma, granulomatous (sarcoid, TB)</li>
<li>Normal PTHrp,VITD - Myeloma, Mets, thyrotropin, Vit A</li>
</ul>
<div id="urinary-calcium-tests" class="section level4">
<h4>Urinary calcium tests</h4>
<p><strong>24 hour urinary collection</strong></p>
<ul>
<li>HCL bottle</li>
<li>Spectrophotometry or atomic absorption spectrophotometry</li>
<li>2.5-7.5 mmol/24 h</li>
</ul>
<p><strong>Fasting spot urinary calcium:Creatinine ratio</strong></p>
<ul>
<li>Males: 0.04-0.45 mol/mol creatinine</li>
<li>Females: 0.10-0.58 mol/mol creatinine</li>
</ul>
</div>
</div>
</div>
<div id="drugs" class="section level1">
<h1>Drugs</h1>
<div id="bisphosphonates" class="section level2">
<h2>Bisphosphonates</h2>
<p><a href="https://cjasn.asnjournals.org/content/4/1/221#sec-2">Nice
overview from Touissant et al CJASN</a></p>
<p>Bisphosphonates</p>
<ul>
<li>Non–nitrogen-containing bisphosphonates are clodronate and
etidronate</li>
<li>Nitrogen-containing bisphosphonates are alendronate, ibandronate,
pamidronate, risedronate, and zoledronate are more potent</li>
<li>low % intestinal absorption, &lt;1-5% - lower if not taken as
directed</li>
<li>When incorporated into bone can hang around in the skeleton for up
to 10 years</li>
<li><strong>Renally metabolised</strong></li>
<li>As released from bone can be recycled and taken up again, or renally
cleared</li>
</ul>
<p><strong>Mechanism</strong></p>
<ul>
<li>Inhibits FFP synthase - &gt; less FPP and GGGPP -&gt; no protein
prenylation-&gt;Kills osteoclasts</li>
</ul>
<p><strong>SE</strong></p>
<ul>
<li>High doses can lead to crystal coating and an associated with
osteomalacia</li>
<li>Off target effects (via FFP) -osteoblastic cells, monocytes ( where
IPP accumulated – bacterial antigen also -&gt; TNF-a and IGN-y release!
– hence flu like symptoms with first bisphosphonate doses). Anergy
prevents subsequent symptoms on next exposures.</li>
<li>Can bind to gastric cells - &gt; cell death -&gt; is this the
mechanism of esophagitis/ulceration</li>
</ul>
<p><strong>Renal toxicity</strong></p>
<ul>
<li>High dose pamidronate can cause collapsing FSGS</li>
<li>Focal glomerular sclerosis (case series of patients with MM)</li>
<li>Pamidronate-induced nephrotic syndrome with renal impairment has
also been reported</li>
<li>ATN</li>
</ul>
<p><strong>Bisphosphonates in CKD</strong></p>
<p><strong>TLDR</strong></p>
<ul>
<li>avoid in low bone turnover, adynamic bone disease, or osteomalacia
are present or suspected, as they have potential to do harm.</li>
<li>Maybe some use in early CKD as osteoporotic prevention</li>
</ul>
<p>A <a href="https://pubmed.ncbi.nlm.nih.gov/16294264/">pooled
metanalysis of 9 trials, n=8996</a> suggests that in CKD 1-3 ( severe
disease excluded from all trials) that when secondary causes of low BMD
are excluded and blood levels of calcium, phosphate, PTH, ALP, and
vitamin D are normal (laboratory features of CKD-MBD), bisphosphonate
use in CKD 1 to 3 is safe and results in fracture reduction</p>
<p>CKD 4-5 not been shown to prevent fractures in people with normal BMD
or with low baseline markers of bone formation, the subset of patients
with severe CKD who might receive therapy would be those with low BMD
but high bone resorption.</p>
<p>By reducing calcium, bisphosphonates may stimulate glandular release
of PTH and induce parathyroid hyperplasia.</p>
<ul>
<li>Pamidronate probably has best (thin) evidence - in multiple myeloma
patients - 10 patients on dialysis</li>
<li>Several case series have described pamidronate use in CKD to be safe
at doses of 60 to 90 mg administered every 1 to 2 mo</li>
<li>Ibandronate 6 HD patients with MM</li>
<li>35-50% removed by HD – varies by drug</li>
</ul>
<p>In chronic use -<strong>1/2 the dose</strong> or reduce the frequency
of administration of bisphosphonates in CKD. Limit treatment to 2
years.</p>
<p>Unclear role in patients with steroids – stick to calcium, vitD</p>
<p>Cochrane review post renal transplantation: no individual
intervention was associated with a reduction in fracture risk compared
with placebo</p>
<p>May result in less atherogensis and vascular calcification but human
data is very limited</p>
<p>Case report level effect in calciphylaxis and other calcific
diseases</p>
</div>
<div id="cinacalcet" class="section level2">
<h2>Cinacalcet</h2>
<div id="evolve-trial" class="section level3">
<h3>EVOLVE Trial</h3>
<p><em>The one that was a bit of a disaster</em></p>
<p><a href="https://www.nejm.org/doi/full/10.1056/nejmoa1205624">Effect
of Cincalcet on CV outcomes in HD</a></p>
<ul>
<li><p>Patients: HD &amp; secondary hyperparathyroidism (sHPT; intact
parathyroid hormone [iPTH] ≥300 pg/ml)</p></li>
<li><p>Outcome: time until death, myocardial infarction, hospitalization
for unstable angina, heart failure, or a peripheral vascular
event.</p></li>
<li><p>Results: n= 3883 | HR in Cincalcet vs placebo 0.93; 95%
confidence interval, 0.85 to 1.02; P=0.11</p></li>
<li><p>Treatment effects of cinacalcet on fracture rates were similar to
effects on CV events in unadjusted ITT analysis</p></li>
<li><p>Not a total wash: Its effective in preventing severe unremitting
HPT but thats a bit soft</p></li>
</ul>
<p><a
href="https://cjasn.asnjournals.org/content/11/3/539">Lessons</a></p>
<ul>
<li>very broad outcomes chosen which mechanistically might not make as
much sense ( all cause death, major CV disease)</li>
<li>Post hoc evaluation of the treatment effects on CV events using
multivariable-adjusted ITT analysis showed relative hazards of 0.88 (95%
confidence interval [95% CI], 0.76 to 1.01) for time to first
atherosclerotic event, 0.79 (95% CI, 0.66 to 0.96) for heart failure,
and 0.79 (95% CI, 0.64 to 0.98) for sudden death; the latter two events
are considered outcomes of nonatherosclerotic disease</li>
<li>Heart failure is a sloppy outcome to record - the event adjudication
committee only confirmed HF in about 50% of the HF dx made by local
investigators</li>
<li>parathyroidectomy as an endpoint was used but the referral pathways
were not concrete and varied geographically so surrogate of calcium
severeity and iPTH levels was used - became a bit murky</li>
<li>age difference in groups despite randomisation</li>
<li>lower event rate than expected</li>
<li>Placebo discontinued for adverse events in 11.8% of patients
compared with 15.8% of patients in the cinacalcet group.</li>
<li>statistical challenges due to the non adherence and
cointerventions</li>
</ul>
</div>
</div>
</div>
<div id="parathyroidectomy-in-ckd" class="section level1">
<h1>Parathyroidectomy in CKD</h1>
<p>RIE Protocol</p>
<div id="pre-operative-care" class="section level2">
<h2>Pre Operative Care</h2>
<ul>
<li>Alfacalcidol 2mcg bd should be given for 3 days prior to
surgery.</li>
<li>Cinacalcet should be stopped one week before parathyroidectomy.</li>
<li>Patients at risk of hungry bone syndrome should be identified.</li>
</ul>
</div>
<div id="hungry-bone-syndrome" class="section level2">
<h2>Hungry Bone Syndrome</h2>
<p>Diagnosis hinges on a profound and persistently low calcium level of
less than 2.1 mmol/L for more than four days postoperatively along with
hypophosphatemia and normal PTH levels. Such patients require prolonged,
high dose calcium to maintain serum calcium levels. Often there is also
associated hypomagnesemia and hypocalciuria. Risk factors include</p>
<ul>
<li>Alkaline phosphatase &gt; 2 times upper limit of normal</li>
<li>PTH levels&gt; 100 pmol/L</li>
<li>Radiologic evidence of bone disease</li>
<li>Higher BMI</li>
<li>Higher BUN</li>
</ul>
</div>
<div id="post-operative-care" class="section level2">
<h2>Post Operative Care</h2>
<ul>
<li>Patients should be admitted to ward 215 post operatively and
prescribed Alfacalcidol 2mcg bd &amp; Calvive (formally Sandocal1000) 2
tablets tds - Do not take at mealtimes.</li>
<li>Hold phosphate binders.</li>
<li>Serum corrected calcium should be measured every 6 hours for the
first 24 hours post surgery, and then less frequently if stable.</li>
<li>Aim for normal serum calcium values (2.2-2.6 mmol/L). Increase
calcium supplementation by 50% if calcium falling and half the dose if
calcium starts to rise.</li>
<li>Pay attention to the trend. If the corrected calcium is falling
rapidly i.e. &gt;10% over 6 hrs the development of significant
hypocalcaemia is likely and requires more frequent monitoring.</li>
<li>If calcium &lt;1.8 or if symptomatic, give IV calcium</li>
<li>Monitor serum phosphate and magnesium 12 hourly for first 24hrs,
then daily.</li>
<li>Do not treat hypophosphataemia unless serum phosphate falls below
0.35 mmol/l.</li>
<li>Consider higher calcium dialysate (A232, A231 containing calcium 1.5
mmol) or PD fluid.</li>
</ul>
</div>
<div id="post-discharge" class="section level2">
<h2>Post Discharge</h2>
<p>RRT patients: Monitor serum calcium on each HD session or 3 times a
week (for PD patients) for the first two weeks and weekly checks as
required thereafter until stability is reached.</p>
<p>The dosing of alfacalcidol and calcium supplements post operatively
is challenging and both hypo- and hypercalcaemia are common. Trends in
concentration are more important than absolute values. Consider the
following:</p>
<ul>
<li>Check adherence and adjust calcium supplement by +- 50%.</li>
<li>Alfacalcidol dose to increase up to a maximum of 5 micrograms bd but
note it takes 3 days to observe effect of increase in dose. Alfacalcidol
product specification recommends increasing dose in increments of 0.25 –
0.5 micrograms but if taking 2 micrograms or more change dose by 1
microgram.</li>
<li>Check magnesium levels and replace if recurrent /resistant
hypocalcaemia</li>
</ul>
</div>
</div>
<div id="iv-calcium-infusion" class="section level1">
<h1>IV Calcium Infusion</h1>
<p>Use calcium gluconate over calcium chloride. Care must be taken to
ensure intravenous calcium is not extravasated. If central line is
available this is likely to be most suitable access. If venous access is
not secure, then a central line may be considered.</p>
<p><strong>Infusion</strong></p>
<ul>
<li>100ml of 10% calcium gluconate (900mg of elemental calcium) +150 ml
of 5% Dextrose (total volume 250 ml). Final concentration is
3.6mg/ml.</li>
<li>Start infusion at 0.3ml/kg/hour (1mg/kg/hour. 70kg patient =
21ml/hr)</li>
<li>Check corrected serum calcium 6 hourly.</li>
<li>Titrate calcium infusion dose between 0-0.6ml/kg/hour to prevent
serum calcium falling below 1.9mmol/L or rising above 2.4 mmol/L.</li>
<li>Severe symptoms include paraesthesia, muscle cramps, carpo-pedal
spasm, laryngeal stridor, convulsions, prolonged QT interval,
arrhythmias, and hypotension. This will require bolus IV calcium and
subsequent infusion.</li>
</ul>
<div id="emergency-calcium-bolus" class="section level3">
<h3>Emergency Calcium Bolus</h3>
<p>Emergency situations - Give 10ml of 10% calcium gluconate (2.2mmol
calcium) no faster than 2ml/min (i.e., Over at least 5mins, ECG
monitoring recommended); this can be given peripherally.</p>
</div>
<div id="common-supplements" class="section level2">
<h2>Common Supplements</h2>
<p>Calcium supplements Calcium Content</p>
<ul>
<li>Adcal (chewable ) 15 mmol / tablet</li>
<li>Calcichew(chewable) 12.6 mmol / tablet</li>
<li>Calvive/ Sandocal 1000 (soluble) 25 mmol / tablet</li>
<li>Calcichew forte(chewable ) 25 mmol / tablet (1 mmol = To 40mg Of
Elemental Calcium)</li>
</ul>
</div>
</div>
<div id="phosphate" class="section level1">
<h1>Phosphate</h1>
</div>
<div id="ckd-mbd" class="section level1">
<h1>CKD-MBD</h1>
<ul>
<li>High-turnover hyperparathyroid bone disease (osteitis fibrosa),
often with abnormal mineralization (mixed uraemic osteodystrophy)</li>
<li>Adynamic bone disease – usually inappropriately low PTH
(historically aluminium deposition)</li>
<li>Association of both conditions with vascular calcification and
calciphylaxis</li>
<li>Many CKD patients have lower bone mass and osteoporotic BMD ( 2.5 SD
below young Caucasian female)</li>
<li>Osteoporosis &amp; metabolic acidosis, low vit D, low activation of
vit D, renal osteodystrophy.</li>
<li>BMD – harder to read in CKD – calcified soft tissues,</li>
<li>Higher rates of #</li>
<li>Quantitative double tetracycline-labelled bone histomorphometry is
gold standard alongside a bone biopsy.</li>
<li>Biopsy is pretty pointless imo unless incredible need to give a
bisphosphonate</li>
</ul>
</div>



</div>
</div>

</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->

<script>
$(document).ready(function ()  {

    // temporarily add toc-ignore selector to headers for the consistency with Pandoc
    $('.unlisted.unnumbered').addClass('toc-ignore')

    // move toc-ignore selectors from section div to header
    $('div.section.toc-ignore')
        .removeClass('toc-ignore')
        .children('h1,h2,h3,h4,h5').addClass('toc-ignore');

    // establish options
    var options = {
      selectors: "h1,h2",
      theme: "bootstrap3",
      context: '.toc-content',
      hashGenerator: function (text) {
        return text.replace(/[.\\/?&!#<>]/g, '').replace(/\s/g, '_');
      },
      ignoreSelector: ".toc-ignore",
      scrollTo: 0
    };
    options.showAndHide = false;
    options.smoothScroll = true;

    // tocify
    var toc = $("#TOC").tocify(options).data("toc-tocify");
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
